Cost-effectiveness analysis of ribociclib versus palbociclib as a first line theraphy in HR+/HER2- advanced breast cancer: evidence from the Chilean public health system
Ribociclib plus letrozole is cost-saving and cost-effective compared to palbociclib plus letrozole for the first-line treatment of postmenopausal women with HR+/HER2- advanced BC in Chile.
Authors
- N. Armijo
- Carlos Balmaceda (ORCID: https://orcid.org/0000-0002-8381-2439)
- Miguel Espinoza (ORCID: https://orcid.org/0000-0003-3718-5582)
Institutions
- Epsilon Systems (United States) (US)
- Bocconi University (IT)
- University of Hong Kong (HK)
Publication Details
- Journal
- Expert Review of Pharmacoeconomics & Outcomes Research
- Published
- 2025-11-21
- DOI
- https://doi.org/10.1080/14737167.2025.2593350
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00